---
title: "Symrise AG Makes Strategic Equity Investment in US Biotech Firm Cellibre"
description: "Symrise AG has made a strategic equity investment in US biotech firm Cellibre, which specializes in precision fermentation. This partnership aims to enhance the development of natural flavor ingredien"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/262237632.md"
published_at: "2025-10-22T12:03:25.000Z"
---

# Symrise AG Makes Strategic Equity Investment in US Biotech Firm Cellibre

> Symrise AG has made a strategic equity investment in US biotech firm Cellibre, which specializes in precision fermentation. This partnership aims to enhance the development of natural flavor ingredients and bioactive cosmetic substances. By collaborating on manufacturing technologies, Symrise seeks to expand its portfolio in taste-balancing solutions and clean beauty ingredients, reinforcing its leadership in sustainable, fermentation-derived products and supporting long-term market competitiveness.

Symrise AG has announced a strategic equity investment in Cellibre, a US-based biotechnology company specializing in precision fermentation. This partnership will allow Symrise to accelerate the development of high-quality, natural flavor ingredients and bioactive cosmetic substances. By collaborating on manufacturing technologies for globally relevant ingredients, Symrise aims to expand its portfolio in taste-balancing solutions and clean beauty active ingredients. The move reinforces Symrise’s leadership in sustainable, fermentation-derived ingredients and supports its long-term competitiveness in the market. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Symrise AG published the original content used to generate this news brief on October 22, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [SYIEY.US - Symrise](https://longbridge.com/en/quote/SYIEY.US.md)
- [SY1.DE - Symrise AG](https://longbridge.com/en/quote/SY1.DE.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Symrise says U.S. Department Of Justice drops antitrust probe | Feb 9 (Reuters) - Symrise AG said on ‌Monday ​that investigations against ‍it ⁠in ⁠U.S. antitrust ‌proceedings ​by the D | [Link](https://longbridge.com/en/news/275308004.md) |
| Harris Associates L.P. increases Symrise AG voting rights to 3.03% | Harris Associates L.P. has increased its voting rights in Symrise AG to 3.03%. No previous percentage is available for c | [Link](https://longbridge.com/en/news/274799291.md) |
| Polaryx Therapeutics Announces SOTERIA Trial Launch for PLX-200 in Krabbe Disease | Polaryx Therapeutics Inc. has announced the launch of the SOTERIA trial to evaluate PLX-200, a therapy for Krabbe diseas | [Link](https://longbridge.com/en/news/275466866.md) |
| Avt Natural Products Ltd Dec-Quarter Consol Profit 173.7 Million Rupees | AVT Natural Products Ltd :AVT NATURAL PRODUCTS LTD - DEC-QUARTER CONSOL PROFIT 173.7 MILLION RUPEESAVT NATURAL PRODUCTS  | [Link](https://longbridge.com/en/news/275575129.md) |
| 10:44 ETWhy PureHealth Research Supplements for Vein Health Are Gaining Traction as a Noninvasive Solution for Restoring Leg Lightness | PureHealth Research's supplements for vein health, particularly VenEase, are gaining popularity as a noninvasive solutio | [Link](https://longbridge.com/en/news/275779736.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.